TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in clear nail linear extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clear nail growth of at least 3 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simultaneous negative culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: LEP (Lower Extremity Performance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: total range of symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Daily Record of Severity of Problems luteal scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood-related symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical symptoms of breast tenderness, bloating, and joint/muscle pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of positive urine cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Side effects lasting longer than 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Recommendation of GnRHa plus add-back
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: postoperative blood transfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major-CRI rate
Endpoint domain: Adverse events/effects
Primary endpoint: QT/QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: endoscopic gastroduodenal ulcer incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Electroclinical remission at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure freedom at last follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects needing acute medical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Central aortic systolic pressure (CASP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: efficacy of IPT-A therapy for adolescent depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: side effect knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of death or transplantation
Endpoint domain: Mortality/survival
Primary endpoint: improvement in LVESV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Annual growth rate for height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Annual growth rate for weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cure rate at 6 months after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aMT6s levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stromal swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Greater decision-making power regarding RHR
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: mean total percentage scores of knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain score in NIH-CPSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lecithin body numbers in prostatic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in illness worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: albumin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent free concentration of drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative 5 year disease-free survival (DFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative 5 year overall survival (OS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Revascularization rate
Endpoint domain: Mortality/survival
Primary endpoint: Event-free clinical course
Endpoint domain: Mortality/survival
Primary endpoint: ICU-acquired weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Snack Points Earned
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in self-care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Increased self-compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hepatic steatosis indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to return of chronic pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Akinesia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supplementation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of supplemental injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Colonic motor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Marginal and internal fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SSV diameters at sapheno‐popliteal junction and calf levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (induration, ecchymosis, paraesthesia, local pain)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain relief in lower back region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of maternal side effects (haemorrhage)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of SPECT in detecting knee pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of SPECT in detecting knee pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of SPECT in detecting knee pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician satisfaction at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spontaneous membrane exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical healing duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of tissue perforations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Role emotional function
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: conjunctival inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ApoB concentration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin temperature increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin blood flow increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Artifact-free pelvic SPECT acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of pelvic bone SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total days on ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for supplemental oxygen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Biochemical Recurrence-Free Survival (BRFS)
Endpoint domain: Mortality/survival
Primary endpoint: PSA values decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA doubling time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with residual tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cosmetic appearance of scars
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Affect improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived distress reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived activation increase
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Volitional control over smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy for managing negative affect without smoking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative emotion expressed in writing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Meaningfulness of writings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Personal and emotional revealing in writings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Haemoglobin increase by > or =20 g/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical short-term outcome of hernia treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgeons' comfort in handling materials
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of patients able to reach the targeted CD34+ cell dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of mobilization failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incident HIV infection
Endpoint domain: Mortality/survival
Primary endpoint: perceived control of asthma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: decrease in beta‐adrenergic inhaler use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness of epidural analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2 levels in the fentanyl group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Wolbachia DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity to fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liking for fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced general depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: greater clinician‐rated improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less impairment in functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Negative urine cannabinoid tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Creatinine adjusted cannabinoid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 30-day postnatal survival
Endpoint domain: Mortality/survival
Primary endpoint: fetal recipient mortality
Endpoint domain: Mortality/survival
Primary endpoint: recipient neonatal mortality
Endpoint domain: Mortality/survival
Primary endpoint: Carotid Pulse Wave Velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient satisfaction with PCA
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported ability to control pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gastric accommodation to a meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in pulmonary capillary wedge pressure from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response latencies to socially anxiety-related stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implicit memory bias for social threat words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HIV‐1 RNA <400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean CD4 cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Psychological distress reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of LVP events per subject
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: parental psychological symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of low biventricular pacing percentage (<97%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent reduction in LVESV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of HF/death and VTA
Endpoint domain: Mortality/survival
Primary endpoint: Rate of ED-administered antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: changes in the quantity of lipid peroxidation products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in protein carbonyl groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in reduced glutathione content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive swabs after 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Risk of positive culture at T1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: adherence to the Mediterranean diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Quality (MQ) of lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD20 distilled water
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PD20 distilled cold water
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: regional wall thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum anti-Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum anti-Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body clearance and volume of distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: V-RQOL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: remission rate at 6 weeks post-test
Endpoint domain: Mortality/survival
Primary endpoint: Severity of liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of HBV-DNA in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of TNS
Endpoint domain: Adverse events/effects
Primary endpoint: Back pain complaints
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year Disease-Free Survival (DFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: 3-year Distant Metastasis-Free Survival (DMFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC(infinity)) of duloxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma drug concentration (C(max)) of duloxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of clinically significant bone loss (> or = 10%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: reduction in total serum cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptoms of anxiety and phobic anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-grade heterotopic ossification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete fusion (grade 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: permanent neurologic deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean mechanical ventilation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: abdominal adipose tissue changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 h urinary sodium concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Natriuresis increase by ACE inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ovarian diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VP (vascular permeability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEDF level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excess mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of grade III‐IV acute GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: 8-Isoprostanes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: puncture times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Perceptions of attaining adequate knowledge and comfort in performing screening otoscopy and tympanometry
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic sensitivity of the CB method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of the CB method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ketoprofen and diclofenac potassium
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of variceal recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Control of acute variceal bleeding
Endpoint domain: Physiological/clinical
Primary endpoint: Symptom levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of smokers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Type 2 diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Salivary cortisol response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: suppressed levels of plasma estradiol and estrone sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage daytime use of hip protectors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modulation of immunologic assays by IFNalpha2b treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decreased expression of Platelet Factor‐4 and Beta‐Thromboglobulin protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease of symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of cccDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roland's disability index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-evaluated health improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ≥1 self-reported quit attempt(s)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retention of associations in long-term memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes